Department of Oncology, Transplants and Advanced Technologies, University of Pisa, Pisa, Italy.
Leuk Res. 2011 Jul;35(7):899-903. doi: 10.1016/j.leukres.2010.10.029. Epub 2010 Dec 4.
The aim of this study was to show a lower incidence of febrile episodes in multiple myeloma patients receiving lenograstim vs. filgrastim after high-dose cyclophosphamide for stem cell mobilization. Patients treated with cyclophosphamide were randomly assigned to receive filgrastim or lenograstim. Primary endpoint was the incidence of febrile episodes. 5.1% patients developed a febrile episode, 9.1% with filgrastim and 1.1% with lenograstim. Lenograstim group presented a significantly higher absolute CD34+ cell number compared with the filgrastim group but no differences were detected for collection efficacy. The study demonstrated a lower incidence of febrile episodes with lenograstim compared to filgrastim.
本研究旨在表明，在接受高剂量环磷酰胺进行干细胞动员后，接受 lenograstim 的多发性骨髓瘤患者发热事件的发生率低于接受 filgrastim 的患者。接受环磷酰胺治疗的患者被随机分配接受 filgrastim 或 lenograstim。主要终点是发热事件的发生率。5.1%的患者发生发热事件，其中 9.1%使用 filgrastim，1.1%使用 lenograstim。与 filgrastim 组相比，lenograstim 组的绝对 CD34+细胞数量明显更高，但采集效果无差异。该研究表明，与 filgrastim 相比，lenograstim 可降低发热事件的发生率。
